DE69731657D1 - Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen - Google Patents

Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen

Info

Publication number
DE69731657D1
DE69731657D1 DE69731657T DE69731657T DE69731657D1 DE 69731657 D1 DE69731657 D1 DE 69731657D1 DE 69731657 T DE69731657 T DE 69731657T DE 69731657 T DE69731657 T DE 69731657T DE 69731657 D1 DE69731657 D1 DE 69731657D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
treating substance
interference
substance use
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69731657T
Other languages
English (en)
Other versions
DE69731657T2 (de
Inventor
Raymond Baker
Roy Curtis
Matthew Elliott
Timothy Harrison
John Hollingworth
Stephen Jackson
Jozef Kulagowski
Melanie Rupniak
Mary Seward
John Swain
John Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69731657(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9625051A external-priority patent/GB9625051D0/en
Priority claimed from GB9701459A external-priority patent/GB9701459D0/en
Priority claimed from GB9713715A external-priority patent/GB9713715D0/en
Priority claimed from GBGB9717097.1A external-priority patent/GB9717097D0/en
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of DE69731657D1 publication Critical patent/DE69731657D1/de
Publication of DE69731657T2 publication Critical patent/DE69731657T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69731657T 1996-12-02 1997-11-25 Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen Expired - Fee Related DE69731657T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB9625051 1996-12-02
GB9625051A GB9625051D0 (en) 1996-12-02 1996-12-02 Therapeutic agents
GB9701459A GB9701459D0 (en) 1997-01-24 1997-01-24 Therapeutic agents
GB9701459 1997-01-24
GB9713715A GB9713715D0 (en) 1997-06-27 1997-06-27 Therapeutic agents
GB9713715 1997-06-27
GB9717097 1997-08-12
GBGB9717097.1A GB9717097D0 (en) 1997-08-12 1997-08-12 Therapeutic agents
PCT/EP1997/006690 WO1998024444A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating substance use disorders

Publications (2)

Publication Number Publication Date
DE69731657D1 true DE69731657D1 (de) 2004-12-23
DE69731657T2 DE69731657T2 (de) 2005-12-01

Family

ID=27451570

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69731657T Expired - Fee Related DE69731657T2 (de) 1996-12-02 1997-11-25 Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen

Country Status (9)

Country Link
US (1) US5919781A (de)
EP (1) EP0942731B1 (de)
JP (1) JP2001504853A (de)
AT (1) ATE282416T1 (de)
AU (1) AU731674B2 (de)
CA (1) CA2273806A1 (de)
DE (1) DE69731657T2 (de)
ES (1) ES2231901T3 (de)
WO (1) WO1998024444A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
US6271230B1 (en) * 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
EP1085875A1 (de) * 1998-06-11 2001-03-28 MERCK SHARP & DOHME LTD. Verwendung von nk-1 rezeptor antagonisten zur behandlung von psychiatrischen krankheiten
JP2002517446A (ja) * 1998-06-11 2002-06-18 メルク シャープ エンド ドーム リミテッド 精神障害の治療のためのｎｋ−１受容体アンタゴニストの使用
AU2003243353A1 (en) * 2002-05-29 2003-12-19 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
GB2394417A (en) * 2002-10-24 2004-04-28 Novartis Ag Solid dispersion comprising a piperidine substance P antagonist and a carrier
US20050065175A1 (en) * 2003-09-24 2005-03-24 Xanodyne Pharmacal, Inc. Oral transmucosal methadone
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
PT533280E (pt) * 1991-09-20 2001-01-31 Glaxo Group Ltd Novas utilizacoes medicas para antagonistas de taquiquinina
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
US5688806A (en) * 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
US5496833A (en) * 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them
DK0737192T3 (da) * 1993-12-29 2001-11-26 Merck Sharp & Dohme Substituerede morpholinderivater og deres anvendelse som terapeutiske midler
WO1996005181A1 (en) * 1994-08-15 1996-02-22 Merck Sharp & Dohme Limited Morpholine derivatives and their use as therapeutic agents
GB9426103D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders

Also Published As

Publication number Publication date
WO1998024444A1 (en) 1998-06-11
AU5559398A (en) 1998-06-29
US5919781A (en) 1999-07-06
ES2231901T3 (es) 2005-05-16
EP0942731B1 (de) 2004-11-17
AU731674B2 (en) 2001-04-05
CA2273806A1 (en) 1998-06-11
JP2001504853A (ja) 2001-04-10
DE69731657T2 (de) 2005-12-01
ATE282416T1 (de) 2004-12-15
EP0942731A1 (de) 1999-09-22

Similar Documents

Publication Publication Date Title
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
DE60022050D1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
ATE267595T1 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten
DE69616480T2 (de) Piperidinderivate als neurokininantagonisten
MX9706969A (es) 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
NO983003L (no) Vitronectin-reseptor-antagonister
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
DE59810761D1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
DE69917230D1 (de) Kombinationspräparat, das selektive nmda nr2b-antagonisten und cox-2 inhibitoren enthält
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE69831409D1 (de) Chalcon-derivate mit antiproliferativer aktivität
ATE282417T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
DE69838882D1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
DE69731657D1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
DE60210101D1 (de) Behandlung von haarfollikeln mit neurokinin 1 rezeptor antagonisten
DE69524623T2 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DK1000046T3 (da) Piperazinderivater, der er aktive på den nedre urinvejskanal
ATE293975T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von kognitiven störungen
DE69732133D1 (de) Verfahren und vorrichtung zur kompensation von durch chrominanzsignalverarbeitung verursachten luminanzstörungen
DE69732492D1 (de) Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee